Skip to content
Clinical Trials Pipeline & In-Development

Trevogrumab

also known as: REGN1033, SAR391786

⚠ Monoclonal antibody — not a classical peptide. A Regeneron anti-myostatin fully human IgG (~150 kDa) being tested as a muscle-sparing adjunct to GLP-1 therapy — CONVERGE combination program with semaglutide in obesity; earlier sarcopenia programs were deprioritized in favor of the obesity opportunity. Included here because it's widely discussed alongside peptides in muscle-sparing conversations.

A fully human monoclonal antibody developed by Regeneron that binds and neutralizes myostatin (GDF-8), reviving prior Phase 2 sarcopenia work within a new "muscle-sparing adjunct to GLP-1" positioning following the success of bimagrumab's BELIEVE Phase 2b combination with semaglutide.

Mechanism of action

Binds myostatin (GDF-8) in circulation, preventing engagement with ActRIIB receptors on skeletal muscle and releasing the myostatin-mediated brake on muscle protein synthesis. Unlike receptor-blockers such as bimagrumab, trevogrumab is a ligand-specific neutralizer — potentially avoiding the off-target effects associated with broader ActRII receptor blockade (BMP9/BMP10 pathway).

Primary uses

  • Muscle preservation during GLP-1 therapy (Phase 2 / CONVERGE program)
  • Historical: sarcopenia (deprioritized)

Typical dosing

not disclosed mg/kg monthly (trial protocols) (intravenous or subcutaneous)

Phase 2 dosing regimens not publicly disclosed in detail.

Regulatory status

Not approved. Regeneron is developing trevogrumab within the CONVERGE program as an adjunct to GLP-1 obesity therapy (paired with semaglutide and/or Regeneron's internal GLP-1 candidate), aiming to preserve lean mass during weight loss. Earlier development in sarcopenia did not advance to approval.

References

  1. [manufacturer] Regeneron Pharmaceuticals. "Pipeline update: CONVERGE muscle-sparing program," investor presentation 2025–2026.
  2. [clinical-trial] ClinicalTrials.gov identifier for Regeneron trevogrumab combination trials in obesity.

Related peptides

Bimagrumab

⚠ Monoclonal antibody — not a classical peptide. A first-in-class muscle-sparing antibody (fully human IgG1, ~150 kDa) against activin type II receptors. Combined with semaglutide in the BELIEVE Phase 2b trial (Nature Medicine, March 2026), it produced greater fat loss than semaglutide alone while preserving lean mass. Not approved; Lilly developer. Included here because it's widely discussed alongside peptides in the muscle-sparing and myostatin conversations.

Apitegromab

⚠ Monoclonal antibody — not a classical peptide. A Scholar Rock fully human IgG (~150 kDa) selective for pro-/latent myostatin (sparing mature myostatin in other tissues) — SAPPHIRE Phase 3 in spinal muscular atrophy read out positive in October 2024; BLA submission in 2025. Platform validation for myostatin biology beyond the muscle-sparing-in-obesity use case.

Semaglutide

A once-weekly GLP-1 receptor agonist FDA-approved for type 2 diabetes and chronic weight management.

Guides & tools

Disclaimer

This entry is for educational purposes only and does not constitute medical advice. Dosing information reflects published regulatory or research data and is not a recommendation. Many compounds described here are not approved for human use in the United States. Consult a licensed medical professional before considering any peptide therapy.